BiotechTube
Dr. Falk Pharma

Dr. Falk Pharma

Freiburg, Germany· Est.
drfalkpharma.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Dr. Falk Pharma is a well-established, research-based private company with over 60 years of expertise in gastroenterology and hepatology. It has successfully transitioned from a development-stage entity to a commercial organization, marketing a portfolio of approved small-molecule therapies for chronic conditions like ulcerative colitis, Crohn's disease, and primary biliary cholangitis. The company leverages its deep therapeutic area knowledge and the scientific platform of the affiliated Falk Foundation to drive innovation and maintain a strong market position in specialized gastrointestinal medicine. Its long-term, family-owned structure supports a focused and patient-centric strategy.

GastroenterologyHepatologyMetabolic Medicine

Technology Platform

Small-molecule pharmaceutical development with expertise in targeted drug delivery formulations for gastrointestinal and hepatic diseases.

Opportunities

Growth in the eosinophilic esophagitis (EoE) market with Jorveza, given increasing diagnosis rates and limited pharmacological options.
Expansion in international markets, particularly in regions with growing prevalence of digestive and metabolic diseases.
Leveraging the Falk Foundation's scientific network to identify and in-license novel late-stage assets in core therapeutic areas.

Risk Factors

Significant reliance on a small portfolio of mature small-molecule products facing generic competition.
Intense competitive pressure from advanced therapies (biologics, novel oral agents) in inflammatory bowel disease, potentially shrinking the addressable market for traditional therapies.
Geographic revenue concentration in Europe, exposing the company to regional pricing and reimbursement pressures.

Competitive Landscape

Dr. Falk Pharma competes in a bifurcated landscape: against large pharma companies with broad GI portfolios and advanced biologics (e.g., AbbVie, Takeda, Janssen) in IBD, and against generic manufacturers for its established small-molecule products. Its differentiation lies in deep specialization, targeted formulations, and a trusted brand built over decades, supported by the independent scientific activities of the Falk Foundation.

More companies in Small Molecule Drugs →More companies in Germany →